US FDA accepts MS drug Lemtrada resubmission for review
US FDA accepts MS drug Lemtrada resubmission for review
The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter...... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1951 Views
-
Last post by frodo
-
- 0 Replies
- 1700 Views
-
Last post by frodo
-
- 0 Replies
- 1326 Views
-
Last post by NHE
-
- 1 Replies
- 1801 Views
-
Last post by frodo
-
- 0 Replies
- 2118 Views
-
Last post by NHE
-
- 0 Replies
- 1251 Views
-
Last post by frodo
-
- 0 Replies
- 2552 Views
-
Last post by NHE
-
- 1 Replies
- 1525 Views
-
Last post by NHE
-
- 0 Replies
- 1858 Views
-
Last post by frodo